Telo Genomics Unveils New Blood Test for Multiple Myeloma MRD Detection at ASH 2025

Telomir Pharmaceuticals, Inc. +1.54% Pre

Telomir Pharmaceuticals, Inc.

TELO

1.32

1.26

+1.54%

-4.43% Pre

Telo Genomics Corp. announced the presentation of initial clinical results from a new method for minimal residual disease (MRD) testing in multiple myeloma at the 67th American Society of Hematology (ASH) Annual Meeting in Orlando, Florida. The study, presented in a poster session and published in the journal Blood, describes an approach combining enumeration of circulating tumor cells (CTCs) from peripheral blood with the TeloView® 3D telomere profiling platform. The method demonstrated a limit of detection of one myeloma cell among 10 million blood cells and identified distinct clusters of 3D genome profiles that correlate with known mutation patterns. Larger studies are underway to validate the predictive value of these MRD profiles for relapse risk.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telo Genomics Corp. published the original content used to generate this news brief on December 18, 2025, and is solely responsible for the information contained therein.
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.